Cross-protective immunity against influenza A/H1N1 virus challenge in mice immunized with recombinant vaccine expressing HA gene of influenza A/H5N1 virus

Song Yang¹², Shumeng Niu¹, Zhihua Guo¹, Ye Yuan¹, Kun Xue¹, Sinan Liu¹ and Hong Jin¹*

Abstract

**Background:** Influenza virus undergoes constant antigenic evolution, and therefore influenza vaccines must be reformulated each year. Time is necessary to produce a vaccine that is antigenically matched to a pandemic strain. A goal of many research works is to produce universal vaccines that can induce protective immunity to influenza A viruses of various subtypes. Despite intensive studies, the precise mechanisms of heterosubtypic immunity (HSI) remain ambiguous.

**Method:** In this study, mice were vaccinated with recombinant virus vaccine (rL H5), in which the hemagglutinin (HA) gene of influenza A/H5N1 virus was inserted into the LaSota Newcastle disease virus (NDV) vaccine strain. Following a challenge with influenza A/H1N1 virus, survival rates and lung index of mice were observed. The antibodies to influenza virus were detected using hemagglutination inhibition (HI). The lung viral loads, lung cytokine levels and the percentages of both IFN-γ⁺CD4⁺ and IFN-γ⁺CD8⁺ T cells in spleen were detected using real-time RT-PCR, ELISA and flow cytometry respectively.

**Results:** In comparison with the group of mice given phosphate-buffered saline (PBS), the mice vaccinated with rL H5 showed reductions in lung index and viral replication in the lungs after a challenge with influenza A/H1N1 virus. The antibody titer in group 3 (H1N1-H1N1) was significantly higher than that in other groups which only low levels of antibody were detected. IFN-γ levels increased in both group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1). And the IFN-γ level of group 2 was significantly higher than that of group 1. The percentages of both IFN-γ⁺CD4⁺ and IFN-γ⁺CD8⁺ T cells in group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) increased significantly, as measured by flow cytometry.

**Conclusion:** After the mice were vaccinated with rL H5, cross-protective immune response was induced, which was against heterosubtypic influenza A/H1N1 virus. To some extent, cross-protective immune response can be enhanced by IL-2 as an adjuvant. Cellular immune responses may play an important role in HSI against influenza virus.

**Keywords:** Influenza virus, Heterosubtypic immunity, Vaccine, Cellular immune response, Cytotoxic T-lymphocytes

* Correspondence: Jinhongf@sina.com

¹Department of Pathogen Biology, China Medical University, Shenyang, Liaoning, PR China

© 2013 Yang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction

Influenza A virus (IAV), a member of the Orthomyxoviridae family, possesses a negative strand RNA genome made up of eight gene segments. Based on surface proteins hemagglutinin (HA) and neuraminidase (NA), IAV are classified 17 HA and 10 NA subtypes [1,2]. Influenza virus undergoes rapid antigenic evolution by accumulation of mutations and through genetic reassortments of segments.

IAV causes frequent epidemics, occasional pandemics and yearly seasonal outbreaks in humans, resulting in significant morbidity and mortality worldwide [3-5]. Vaccination has been one of the most effective means of protection against IAV. Due to the constant antigenic evolution of IAV, influenza vaccines must be reformulated each year. Although these vaccines are efficacious, they arrive late and after the peak of a pandemic. Therefore, we wish to investigate universal vaccines that can induce protective immunity to IAV of various subtypes [6]. Heterosubtypic immunity (HSI) is the basis of creating universal influenza vaccines. Evidence supports that cytokines and T cell responses play crucial roles in HSI to influenza virus [7,8]. Despite intensive studies, the precise mechanisms of HSI remain ambiguous.

In this study, mice were vaccinated with recombinant virus vaccine (rL H5), in which the HA gene of influenza A/H5N1 virus was inserted into LaSota Newcastle disease virus (NDV) vaccine strain. The mice were then challenged with influenza A/H1N1 virus. Furthermore, we co-administered intraperitoneally recombinant murine interleukin-2 (rIL-2) with the rL H5 to enhance HSI.

We found that vaccination with rL H5 provided cross-protection against a lethal challenge with an antigenically distinct influenza A/H1N1 virus and produced significant changes in the levels of some cytokines and the percentages of both IFN-γ+CD4+ and IFN-γ+CD8+ T cells in lung and spleen. We also found that rIL-2 co-administered with the rL H5 could increase the survival rate of mice, reduce viral replication in lung and improve the IFN-γ production.

Results

Clinical outcome and lung index following influenza A/H1N1 virus infection

To determine whether primary immunization with the rL H5 vaccine can protect against a subsequent infection with heterosubtypic influenza virus, female 6–8 weeks-old C57BL/6 mice were immunized with the rL H5 vaccine and infected with influenza A/H1N1 virus with or without IL-2. The mice were monitored for body weight loss and survival rates.

The mice in group 2 (rL H5 + IL-2-H1N1) and group 3 (H1N1-H1N1) all survived after infection. The survival rate of mice in group 1 (rL H5-H1N1) was 58% at day 14 post-infection (p.i.). The mice in group 4 (PBS-H1N1) were all dead at day 7 p.i. (Figure 1A). The survival rate of group 2 (rL H5 + IL-2-H1N1) was higher than the survival rate of group 1 (rL H5-H1N1). Mice vaccinated with NDV were all dead at day 7 p.i. (data not shown). These results demonstrated that there was cross-protection between the H5 and H1 subtypes of influenza virus and that IL-2 as adjuvant could increase the survival rate of mice. NDV and IAV had not cross-protection.

The low lung index correlated well with strong protection during IAV infection. The lung index of group 1 (rL H5-H1N1) was 0.87%, group 2 (rL H5+IL-2-H1N1) was 0.74%, and group 4 (PBS-H1N1) was 1.51% at day 7 p.i. The lung indexes of group 1 and group 2 were lower than in group 4 at day 7 p.i. (P < 0.05) (Figure 1B). These data showed that rL H5 vaccine could prevent the mice from weight loss and inflammation of lung when they were challenged with influenza A/H1N1 virus.

Viral load in the lungs of mice

The viral loads in the lungs of the mice were assessed using a real-time RT-PCR method at day 5 p.i. (Figure 1C). The lung viral loads of group 1 (rL H5-H1N1) and group 2 (rL H5+IL-2-H1N1) were significantly lower than group 4 (P < 0.05). The lung viral loads of group 2 were lower than group 1 (P < 0.05). These data demonstrated that rL H5 induced cross-protection against A/H1N1 virus infection which may be enhanced by IL-2.

Hemagglutination inhibition antibody responses

To determine whether the antibody had the protective effect against influenza A/H1N1 virus, we detected the levels of antibodies against influenza A/H1N1 virus in sera of mice by Hemagglutination inhibition (HI) assay (Table 1). The antibody titer in group 3 (H1N1-H1N1) was 640 at day 14 p.i.. It was significantly higher compared with the other groups that only low levels of antibody were detected. These data demonstrated that the levels of antibody might play a critical role in homologous influenza virus infection, but showed a negative correlation between HSI and antibody levels.

Cytokine expression in the lungs of mice

Lung suspensions were analyzed for Th1-type and Th2-type cytokine levels using ELISA. High levels of IFN-γ were detected in group 1 (rL H5-H1N1) and group 2 (rL H5+IL-2-H1N1). The IFN-γ and IL-10 levels of group 1 (rL H5-H1N1) were significantly higher than in group 3 (H1N1-H1N1) at day 7 p.i. (P < 0.05). The IFN-γ level of group 2 (rL H5+IL-2-H1N1) was significantly higher than in group 1 (rL H5-H1N1) at day 7 p.i. (P < 0.05). The IFN-γ and IL-10 levels of group 1 and group 2 were significantly elevated after infection as compared to day 0 (P < 0.05) (Figure 2A and D).
The IL-2 and IL-4 levels were not significantly different in all groups of mice (Figure 2B and C). These results suggested that IFN-γ and IL-10 may play roles in HSI. IL-2 co-administrated with rL H5 vaccine could improve the IFN-γ production.

The percentages of both IFN-γ⁺CD4⁺ T cells and IFN-γ⁺CD8⁺ T cells in spleen

To investigate the roles of Th1 lymphocytes and cytotoxic T-lymphocytes (CTL) in HSI to influenza virus, the percentages of IFN-γ⁺CD4⁺ and IFN-γ⁺CD8⁺ T cells in spleen were assessed using flow cytometry. The percentages of IFN-γ⁺CD4⁺ and IFN-γ⁺CD8⁺ T cells had not significant change at day 5 p.i.. The percentages of IFN-γ⁺CD4⁺ T cells of mice group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) were significantly higher than in group 3 (H1N1-H1N1) and group 4 (PBS-H1N1) at day 7 p.i. (P < 0.05) (Figure 3A). The percentages of IFN-γ⁺CD8⁺ T cells of mice group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) were significantly higher than in group 4 (PBS-H1N1) at day 7 p.i. (P < 0.05) (Figure 3B). These data demonstrated that rL H5 vaccine induced high frequencies of Th1 cells and CTL.

Discussion

HSI to influenza virus can be successfully induced by live or inactivated whole influenza viruses or DNA vaccines in different kinds of animals [9-13]. In our research, we primed mice with NDV-based recombinant virus vaccine expressing HA gene of influenza A/H5N1

| Experimental group | Antibody titers against H1 virus (HI) |
|--------------------|--------------------------------------|
|                    | Day 7 | Day 14 |
| rLH5-H1N1          | <40   | <40   |
| rLH5 + IL-2-H1N1   | <40   | <40   |
| H1N1-H1N1          | 320   | 640   |
| PBS-H1N1           | n.d.  | n.d.  |
| IL-2-H1N1          | <40   | n.d.  |

A titer of <40 represents the lower limit of detection. n.d. = not done. Animals did not survive until these time points.
virus (rLH5), and induced cross-protection to influenza A/H1N1 virus infection from severe disease, death and viral replication in the lungs. Ge et al. [14] demonstrated that the NDV portion of rLH5 vaccine protected mice from NDV infection and could not provide protection from influenza A/H5N1 virus infection. We also found that the NDV portion of vaccine does not elicit cross-protection against influenza A/H1N1 virus infection (data not shown). Therefore, the protective efficacy of HSI in our experiments was induced by gene of influenza virus in rLH5 vaccine.

Current vaccines generate neutralizing antibodies directed against viral HA and NA surface glycoproteins of homologous influenza viruses [15]. According to Genbank (ADG59526.1 and AAC53844.1), the amino acid homology of HA of A/Font Monmouth/1/1947 (H1N1) and A/Bar-headed goose/Qinghai/3/2005 (H5N1) was 62%. In this study, antibodies against influenza A/H1N1 virus in sera were determined by HI assay after infection. The results showed a strong antibody response to influenza A/H1N1 virus in group 3 (H1N1-H1N1) that played a critical role in immune responses to homologous influenza virus infection. We observed low or undetectable levels of antibodies to influenza A/H1N1 virus in the other groups. It indicated a negative correlation between HSI and antibody levels.

We found that the IFN-γ and IL-10 levels in the lung samples from group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) were significantly high after infection in comparison to the other groups. IFN-γ, a Th1 cytokine, can enhance the phagocytic function of macrophages and the cytotoxic effect of NK cells. CTL, which can lyse target cells and prevent spread of influenza virus in vivo, can be activated by IFN-γ [8,16-18]. IL-10 is an anti-inflammatory cytokine. Although IL-10 is a Th2 cytokine, it can inhibit the generation of inflammatory mediators and prevent imbalances of the inflammatory reaction [19]. High levels of IFN-γ and IL-10 can help clear influenza virus, combat excessive inflammation and promote recovery.

T-cell-mediated immune responses are an important factor in HSI to influenza virus. IFN-γ+ CD4+ T cells are Th1 cells and IFN-γ+ CD8+ T cells are effector CTL that are critical features of an adaptive immune system [20-22]. In this study, high frequencies of activated IFN-γ+ CD4+ and IFN-γ+ CD8+ T cells in mice of group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) were elicited by influenza A/H1N1 virus challenge. It indicated that T-cell-mediated immunity might play an important role in cross-protection between different subtypes of influenza virus.

Vaccines that broadly induce cross-reactive T cell responses are usually directed against conserved viral epitopes of internal proteins, such as NP proteins [23,24]. De Groot et al. [25] reported that the HA also possesses cross-conserved T-cell epitopes [26-28]. We had found that there was no correlation between the levels of antibody and HSI against influenza virus. And our results showed that the levels of IFN-γ and the percentages of both IFN-γ+ CD4+ and IFN-γ+ CD8+ T cells in group 1 (rL H5-H1N1) and group 2 (rL H5 + IL-2-H1N1) increased significantly after infection. We speculate that
the cross-protection against heterosubtypic influenza A/H1N1 viruses in mice may be due to cross-conserved T-cell epitope sequences in HA.

Some researchers have used various adjuvants such as IL-2, IL-12, GM-CSF or the heat-labile enterotoxin from enterotoxigenic Escherichia coli to improve immune responses [29,30]. In this study, we selected rIL-2 as an adjuvant to enhance HSI. We found that the mice in the group that co-administered with IL-2 had higher survival rates, lower viral loads and greater amount of IFN-γ production. Henke et al. [31] reported that IL-2 increased the efficacy of DNA immunization to prevent influenza virus infections, IL-2 as an adjuvant for vaccination can stimulate the proliferation and activation of T cells, NK cells and macrophage. It can also enhance cellular immunity [32]. Further studies will be done to clarify the mechanism that IL-2, as an adjuvant, enhance HSI.

In summary, rLH5 vaccine induced cross-protective immune response against heterosubtypic influenza A/H1N1 virus infection in mice, and this cross-protection was improved with IL-2 as an adjuvant. T cell immunity may play an important role in HSI against influenza virus. Further studies will be necessary to determine the most effective cross-conserved T-cell epitope to HSI and the precise mechanism of HSI.

**Materials and Methods**

**Mice**

Healthy female C57BL/6 mice 6–8 weeks of age were obtained from the Laboratory Animal Center of China Medical University. Mice were bred and/or housed under specific pathogen-free (SPF) conditions until the day of sacrifice. The Institutional Ethics Committee for
Animal Use and Care approved all animal-related experiments and procedures.

**Influenza virus and vaccine**

Influenza viruses A/Font Monmouth/1/1947 (A/FM/1/47) (H1N1) were propagated in the allantoic cavity of 10 day-old embryonated SPF chicken eggs at 34°C, and allantoic fluid was harvested after 2–3 days. Fifty percent egg infectious dose (EID<sub>50</sub>) titers were determined by serial titration of viruses in eggs and calculated by the method of Reed and Muench [8].

rL H5 vaccine was purchased from Harbin Veterinary Research Institute. HA open reading frame from A/Bar-headed goose/Qinghai/3/2005 (H5N1) were inserted into the intergenic region between the P and M genes of the LaSota NDV vaccine strain.

**Immunization and challenge of mice**

Mice were anesthetized by intraperitoneal injection with tribromoethanol (Avertin; 250 to 300 μl per mouse) [33]. Mice were intranasally inoculated with 10<sup>6.0</sup> EID<sub>50</sub> of rL H5 vaccine in a volume of 50 μl. Three weeks later, the mice were re-immunized in the same manner with the same amount of the vaccine. Two weeks after re-immunization, mice were intranasally infected with 10<sup>4.8</sup> EID<sub>50</sub> of influenza A/H1N1 virus in a volume of 50 μl. Mice were divided into six groups (Table 2). Group 1 (rL H5-H1N1): Mice were primed with rL H5 vaccine and infected with influenza A/H1N1 virus as described above; Group 2 (rL H5 + IL-2-H1N1): Mice were primed with rL H5 vaccine and 160 U of rIL-2 in a volume of 100 μl PBS was co-administered intraperitoneally 3 days after the primary and secondary immunization. Mice were challenged with influenza A/H1N1 virus as in group 1; Group 3 (H1N1-H1N1): Mice were intranasally inoculated with 10<sup>2.8</sup> EID<sub>50</sub> of influenza A/H1N1 virus in a volume of 50 μl and were challenged with influenza A/H1N1 virus as in group 1 [20]; Group 4 (PBS-H1N1): Mice were given PBS in a volume of 50 μl and were challenged with influenza A/H1N1 virus as in group 1; Group 5 (IL-2-H1N1): Mice were injected intraperitoneally with rIL-2 in the same manner as group 2 and were challenged with influenza A/H1N1 virus as in group 1; Group 6: Negative control group.

Mice (n = 12/group) were monitored daily for body weight and survival rates after infection. At day 0, 5 and 7 p.i., mice were euthanized and their lungs and spleen were resected.

**Lung index assays**

Three mice from each group were euthanized and their lungs were weighed. Lung index is expressed as percentage of weight, according to the formula: lung weight/ body weight × 100%.

**HI assay**

Mice (n = 3) from each group were bled via the orbital sinus vein and the sera were collected at day 7 and 14 p.i.. HI assay was performed as previously described [34,35].

**Cytokine assays**

Intact lungs of mice (n = 3) from each group were prepared to assess cytokine levels at days 0 and 7 p.i.. Whole lungs were homogenized using a conventional method [36]. Homogenates were centrifuged at 300 g for 10 min., and supernatants were collected. The amounts of interferon-γ (IFN-γ), IL-2, IL-4 and IL-10 in lung suspensions were measured using ELISA as described previously [34].

**Flow-cytometric analysis**

The virus-specific IFN-γ<sup>+</sup>CD4<sup>+</sup> and IFN-γ<sup>+</sup>CD8<sup>+</sup> T cells were analyzed using flow cytometry. Splenocytes of mice (n = 3) from each group were collected at day 0, 5 and 7 p.i.. Single-cell suspensions were prepared as previously described [9]. 1 × 10<sup>6</sup> splenocytes were plated to a 96-well flat-bottom plate and stimulated with infectious influenza A/H1N1 virus at an MOI of 0.1 in 200 μl volume for 21 h [27]. Breduflidin A (BD GolgiPlug) was added at a final concentration of 1 μg/ml for the last 5 h of incubation to block protein transport. Cells were stained intracellularly for fluorescein isothiocyanate (FITC)-anti-INF-γ after surface staining for Peridinin-Chlorophyll-Protein Complex (PerCP)-anti-CD3, phycoerythrin (PE)-anti-CD4 or PE-anti-CD8b (Becton Dickinson). Stained cells were quantified using a FACS Calibur (BD Biosciences) and analysed using the FlowJo software (Treestar).

**Virus quantification assays**

Lung suspensions of mice (n = 3) from each group were prepared at day 5 p.i.. Influenza virus in the lung

---

**Table 2 Experimental groups**

| Experimental group | Vaccination | H1N1 challenge |
|--------------------|-------------|----------------|
|                    | Recombinant virus vaccine | Adjuvant |
| Group 1 (rLH5-H1N1) | + | - | - | + |
| Group 2 (rLH5 + IL-2-H1N1) | + | + | - | + |
| Group 3 (H1N1-H1N1) | - | - | + | + |
| Group 4 (PBS-H1N1) | - | - | - | + |
| Group 5 (IL-2-H1N1) | - | + | - | + |
| Group 6 | - | - | - | - |
susceptions was quantified using real-time RT-PCR [37]. Total virus RNA was prepared using the RNAiso Plus (TaKaRa) following the manufacturer’s instructions. The primer sequences used for RT-PCR and quantitative real time PCR of the viral NP gene were 5'-CTGAGAAA GCAGGTACTGGGC-3' (sense) and 5'-CTGCATTGTCCCGAAAGAT-3' (antisense).

Real-time RT-PCR was performed using the SYBR® PrimeScript® RT-PCR kit (Perfect Real Time, TaKaRa). A 20 μl reaction volume was prepared according to the manufacturer’s instructions. Cycling conditions for real-time RT-PCR were as follows: 37°C for 15 min, 85°C for 5 s, 95°C for 30 s followed by 40 cycles of 95°C for 5 s, 55°C for 34 s. Real-time RT-PCR was conducted using the ABI 7500 and the data were analyzed using ABI software.

Conventional RT-PCR was carried out using the extracted RNA and primers as described above. The concentration of the RT-PCR product was determined by measuring the OD at 260 nm using a spectrophotometer (Eppendorf) [38]. Serial 10-fold dilutions of the product DNA with EASY dilution (TaKaRa) were used in real-time PCR and the standard curve generated from the amplification plot.

Statistical analysis

Statistical analyses were carried out using the SPSS 17.0 software. The differences between values were evaluated through a one-way analysis of variance (ANOVA) followed by pair-wise comparison with the Student-Newman-Keuls test. P < 0.05 was considered statistically significant and all values are expressed as means ± SEM. All experiments were performed at least three times.

Acknowledgements

We gratefully acknowledge the financial support of Ministry of Education of the Peoples Republic of China (20102104110018). We gratefully acknowledge the technical assistance from Yaming Cao, Fengping Shan, Miao Li and Jun Liu. We also acknowledge BioMed Proofreading for native English-speaking experts’ edition.

Author details

1 Department of Pathogen Biology, China Medical University, Shenyang, Liaoning, PR China. 2 Department of animal husbandry and veterinary, Liaoning Medical University, Jin Zhou, Liaoning, PR China.

References

19. Tong SX, Li Y, Rivallear P, Comarand C, Castillo DA, Chen LM, Recuenco S, Ellison JA, Davis CT, York IA, Turmelle AS, Moran D, Rogers S, Shi M, Tao Y, Wei MR, Tang K, Rowe LA, Sannons S, Xu X, Face R, Lindblade KA, Cox NJ, Anderson L, Rupprecht CE, Doris RO. A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A 2012, 109:4269–4274.
20. Zhu XY, Yu WL, McBride R, Li Y, Chen LM, Donis RO, Tong S, Paulson JC, Wilson IA. Hemagglutinin homologue from H17N10 bat influenza virus exhibits divergent receptor-binding and pH-dependent fusion activities. Proc Natl Acad Sci U S A 2013, 110:14558–1463.
21. He W, Han H, Wang W, Gao B. Anti-influenza virus effect of aqueous extracts from dandelion. J Virol 2011, 85:358–358.
22. Manicassamy B, Medina RA, Hai R, Tilbume T, Stertz S, Nistal-Villain E, Palep P, Baker CF, Garcia-Sastre A. Protection of mice against lethal challenge with 2009 H1N1 influenza A virus by 1918-like and classical Swine H1N1 based vaccines. PLoS Pathog 2010, 6: http://dx.doi.org/10.1371/journal.ppat.1000745.
23. Palese P, Shaw ML. Orthomyxoviridae: the viruses and their replication. In: Fields virology, 5th edition. Edited by Howley PA MM. . 2011:1647–1689.
24. Bodeliews R, Krejtz JH, Gheelhoid-Mieras MM, van Amerongen G, Verburgh RJ, van Trierem SE, Kukien T, Fouchier RA, Osterhaus AD, Rimmelzaaw GF. Vaccination against seasonal influenza A/H3N2 virus reduces the induction of heterosubtypic immunity against influenza A/H5N1 virus infection in ferrets. J Virol 2011, 85:2695–2702.
25. Lu X, Edwards LE, Desheva JA, Nguyen DC, Rekstin A, Stephenson I, Szretter K, Cox NJ, Rudenko LG, Klimov A, Katz JM. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A(H5N1) viruses. Vaccine 2006, 24:6588–6593.
26. Seo SH, Peirs M, Webster RG. Protective cross-reactive cellular immunity to lethal A/Goose/Guangdong/1/96-like H5N1 influenza virus CD8+ T cell expressing gamma interferon. J Virol 2002, 76:4686–4690.
27. Krejtz JH, Bodeliews R, van den Brand JM, de Mertt G, Bas C, van Amerongen G, Fouchier RA, Osterhaus AD, Rimmelzaaw GF. Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H7N3 virus. Vaccine 2009, 27:4985–4989.
28. Chen Q, Madson D, Miller CL, Harris DL. Vaccine development for protecting swine against influenza virus. Annu Health Res Rev 2012, 13:81–195.
29. Hikono H, Mase M, Matsuu A, Nakayama M, Saito T. Intraocular vaccination with an inactivated highly pathogenic avian influenza virus induces protective antibody responses in chickens. Vet Immunol Immunopathol 2013, 151:83–89.
30. Huang B, Wang W, Li R, Wang X, Jiang T, Qi X, Gao Y, Tan W, Ruan L. Influenza A virus nucleoprotein derived from Escherichia coli or recombinant vaccinia (Tiantan) virus elicits robust cross-protection in mice. J Virol 2012, 9:322–334.
31. Prabakaran M, Kolpe AB, He F, Kwang J. Cross-protective efficacy of bivalent recombinant baculoviral vaccine against heterologous influenza H5N1 challenge. Vaccine 2013, 31:1385–1392.
32. Ge J, Deng G, Wen Z, Tian G, Wang Y, Shi J, Wang X, Li Y, Hu S, Jiang Y, Yang C, Yu K, Bu Z, Chen H. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 2007, 81:1592–1598.
33. Teijaro JR, Verhoeven D, Page CA, Tumer D, Farber DL. Memory CD4 T cells direct protective responses to influenza virus in the lungs through helper-independent mechanisms. J Virol 2010, 9:2177–2220.
34. Rimmelzaaw GF, Boon AC, Gheelhoid MM, Voeten JT, Fouchier RA, Osterhaus AD. Human airway epithelial cells present antigen to influenza virus-specific CD8+ CTL inefficiently after incubation with viral protein together with ISCOMATRIX. Vaccine 2004, 29:2769–2775.
Cross-protective immunity against influenza virus infection in mice without antibodies. J Immunol 1998, 160:322–327.

27. Brewoo JN, Powell TD, Jones JC, Gundlach NA, Young GR, Chu H, Das SC, Hessel A, Schwendinger M, Holzer GW, Orlinger KK, Coulibaly S, Savidis-Mastorakos E, De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD, Katz JM, Lu X, Young SA, Galphin JC, Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A, Slpushkin VA, Black RA, Gamble WC, Rota PA, Cox NJ. Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2009 pandemic H1N1 influenza A virus. J Virol 2010, 84:3312–3319.

28. Bui HH, Peters B, Assarsson E, Mbawuike I, Sette A. Cross-recognition of avian H5N1 influenza virus by human cytotoxic T-lymphocyte populations directed to human influenza A virus. J virology 2008, 82:5161–5166.

29. Tu W, Mao H, Zheng J, Liu Y, Chiu SS, Chan PL, Lam KT, Guan J, Zhang L, Guan Y, Yuen KY, Peris JS, Lau YL. Cytotoxic T lymphocytes established by seasonal human influenza cross-react against 2009 pandemic H1N1 influenza virus. J virol 2010, 84:6527–6535.

30. White NW, Amshey BN, G’Sell DJ, Thanheiser D, Staggs D, Nordstrom DA, Portnoy DA, Zhang L, Guan Y, Yuen KY, Peris JS, Lau YL. The efficacy of seasonal influenza vaccines in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA virus vaccine. PLoS ONE 2011, 6: e19013.

31. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

32. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

33. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

34. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

35. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

36. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

37. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

38. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

39. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

40. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

41. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.

42. Broman M, Hamming OJ, Hartmann R, Ziegler T, Julkunen I, Kandil A, James O, Underdown B, Klein M, Katz J, Burt D. Heterosubtypic immunity against human influenza A viruses, including pandemic A(H1N1) virus, in mice against influenza A virus challenge by vaccination with baculovirus-expressed H5N1 HA vaccine. J virology 2010, 84:5704–5713.